Volume Alert - ABT 43.49 Abbott Laboratories $ABT
Post# of 70
Posted On: 11/18/2014 12:51:33 PM
Volume Alert - ABT 43.49 Abbott Laboratories $ABT Hit a high today of 43.82 Closing the day 10:30 at 43.49 -0.22 -0.50% With a day low of 43.47 and a total volume of 1,463,405.
ABT Recent Posts: http://investorshangout.com/Abbott-Laboratories-ABT-49973/
ABT Abbott Laboratories Recent Headline News
Cancer Diagnostics (Tumor Biomarker Tests, Imaging, Endoscopy and Biopsy) Market 2014 - 2020
M2 - 2 hrs 20 mins ago
Research and Markets (http://www.researchandmarkets.com/research/cgz62c/cancer) has announced the addition of the "Cancer Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. Imaging, endoscopy, biopsy and tumor biomarker tests altogether comprise the global cancer diagnostics market. Imaging for cancer detection remains the largest segment in the cancer diagnostics market owing to its utilization in detection of almost every cancer type. MRI, PET, CT, mammography and ultrasound are the major imaging modalities, of which, CT scan and ultrasound imaging account for more than two-third of the total cancer imaging market. A tumor biomarker test is a segment in the cancer diagnostics market with highest research activity. Cancer biomarkers are increasingly being applied in cancer diagnostics; a highly sensitive and specific biomarker essentially helps in better diagnosis, monitoring and prognosis of cancer. Protein-based biomarkers such as alpha-fetoprotein (AFP), cancer embryonic antigen (CEA), prostate-specific antigen (PSA) are among the prominently used tumor biomarkers. The market for cancer diagnostics is majorly driven by demand from the patients affected with cancers of lung, breast, and colorectal cancer. Lung cancer is the most common cancer of all types and approximately 1.8 billion new cases of lung cancer were diagnosed in 2012. The increasing use of tobacco products in developing nations, particularly in BRICS countries, is contributing to the growing prevalence of lung cancer in the world. In 2013, the global lung cancer diagnostics market accounted for one-fourth of the global cancer diagnostics market revenue. In addition, the rising prevalence of breast cancer among women across the world, particularly in the Asia Pacific, is expected to drive the market for breast cancer diagnostics at the highest CAGR of 8.2% during the forecast period 2014 to 2020. The global cancer diagnostics market is led by players such as Abbott Laboratories, Ambry Genetics, AstraZeneca, bioMerieux, Eli Lilly and Co., Roche, GlaxoSmithKline plc, Novartis, and Pfizer. Scope of the Report Tumor Biomarker Tests: - PSA Tests - CTC Tests - AFP Tests - CA 19-9 - CA 125 - EGFR - HER2 - CEA - BRCA - KRAS - ALK Imaging - MRI Scan - PET Scan - CT Scan - Mammography - Ultrasound Endoscopy - Bronchoscopy - Colonoscopy - Sigmoidoscopy - Colposcopy - Others Biopsy - Bone Marrow Biopsy - Needle Biopsy - Endoscopic Biopsy Cancer Diagnostics Market, by Application: - Leukemia - Breast Cancer - Colorectal Cancer - Kidney - Liver - Lung - Ovarian - Pancreatic - Prostate Companies Mentioned - Abbott Laboratories, Inc. - Ambry Genetics - AstraZeneca plc - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Genoptix, Inc. - GlaxoSmithKline plc - Pfizer, Inc. - bioMeriux SA For more information visit http://www.researchandmarkets.com/research/cgz62c/cancer
ABT: 43.67 (-0.04), PFE: 30.66 (+0.34), AZN: 73.72 (+1.22), LLY: 67.95 (+0.66), GSK: 46.12 (+0.24), NVS: 95.58 (+1.20)
qPCR and dPCR Markets (Instruments, Reagents, Software/Services, Clinical and Research Markets) Report 2013-2018
M2 - 2 hrs 25 mins ago
Research and Markets (http://www.researchandmarkets.com/research/tv8xlw/qpcr_and_dpcr) has announced the addition of the "qPCR and dPCR Markets (Instruments, Reagents, Software/Services, Clinical and Research Markets)" report to their offering. Real time qPCR is considered the gold standard for accurate, sensitive, and fast quantification of nucleic acid sequences. PCR technologies, specifically qPCR (quantitative PCR) and digital PCR (dPCR) show significant promise for growth. qPCR is mainly a workhorse in the research laboratory, while dPCR is helping to push the potential for diagnostic applications due to its sensitivity, precision, robustness and reproducibility. qPCR has been established for a broad range of applications including gene expression, genotyping, pathogen detection, DNA methylation analysis. qPCR is increasingly being used in the medical diagnostic arena for diagnosis of bacterial disease, detection of antibiotic resistance, diagnosis of infectious disease and quantification of bacterial load. It is also used to detect genetic abnormalities and cancer mutations. qPCR-based diagnostic tests are expected to expand in the coming years. dPCR provides absolute measurement of copies and would seem to be the next logical step in PCR evolution. dPCR partitions the sample and reaction components into hundreds or thousands of reaction chambers to count the presence or absence of molecules. It provides greatly improved sensitivity in the detection of rare mutations and sequences. This technology will become increasingly important in the clinical application of PCR. Segments Include: - Clinical Market for qPCR - Research Market for qPCR - Clinical Market for dPCR - Research Market for dPCR - qPCR Instruments - qPCR Reagents - qPCR Software and Services - dPCR Instruments - dPCR Reagents - dPCR Software and Services Some of the market drivers influencing participation: - A global aging population - An increase in the number of population affected by chronic medical conditions - Advancements in gene detection and technologies - The increasing role of diagnostics in home health and remote patient care - Personalized medicine - Advancements next generation sequencing and multi-gene approaches Challenges facing those in the market, including: - Development financial, time investment risk - Uncertain regulatory environment - Cost to patient may limit accessibility in many regions - Economic uncertainty: patients are likely to decline advanced testing in times of hardship - New technologies more difficult to develop Some of the issues and trends affecting this market are: - BRIC Involvement - qPCR and Robotics - Lab-on-a-Chip Devices - Molecular Testing Reimbursement Companies profiles in this report include: - Abbott Laboratories - Affymetrix - Aglient Technologies - Analytik Jena AG - Becton Dickinson - BioFire Diagnostics - bioMerieux - Bio-Rad Laboratories - Cephid - Denville Scientific - Eppendorf AG - Exiqon A/S - Fluidigm - Illumina - Kyratec - Life Techologies - Promega - Qiagen - RainDance Technologies - Roche - Sacace Biotechnologies - Takaro Bio - Thermo Fisher Scientific - WaferGen Biosystems For more information visit http://www.researchandmarkets.com/research/tv...r_and_dpcr
ABT: 43.67 (-0.04)
Advanced Remote Patient Monitoring Systems Market Report: 2014 Edition
M2 - 2 hrs 31 mins ago
Research and Markets (http://www.researchandmarkets.com/research/f348f9/advanced_remote) has announced the addition of the "Advanced Remote Patient Monitoring Systems, 7th Edition" report to their offering. For their potential to reduce healthcare costs and improve patient outcomes, patient monitoring systems with advanced capabilities are among the fastest-growing devices in terms of revenue growth. In recent years, there's been demand from healthcare organizations for monitors with remote reporting functions and EMR transfer. Advanced Remote Patient Monitoring Systems, is a comprehensive study on the patient monitoring industry, including the advanced system with remote and wireless capability to includes patient monitoring equipment and devices which have advanced features. The report specifically focuses on technologically advanced (including wireless and remote) patient monitors; monitors with patient data processing applications; and monitors which are capable of data transfer to an EMR system-including equipment and peripherals which coordinate the flow of data to hospital electronic medical record systems. For the most part, devices covered in this report can: 1) provide monitoring information beyond a patient room; and 2) provide data for an EMR system or are expected to add such features within the forecast period. This report provides complete market sizes and revenue breakouts for the important segments of the advanced monitoring market. For the purpose of this report, three general areas of advanced patient monitoring are covered. - Blood Management and Function Monitors - Glucose Monitor, Blood Pressure Monitor, PT/INR, Other - Cardiac Event and Function Monitors - Cardiac Event, EKG/ECG - Neurological Event Monitors - Respiratory Function Monitors - Anesthesia - General - Sleep Apnea There are a considerable number of companies offering some form of wireless and remote technologies, patient data processing applications and equipment, and EMR data transfer equipment. A select few are profiled in this report including: - Abbott Laboratories - Aerotel Medical Systems - Alere - AMD Global Telemedicine - American TeleCare - AuthentiDate - B. Braun - Baxter - Bosch - Boston Scientific - C.R. Bard - Cardiocom - Carematix - Compumedics . - Covidien - Criticare Systems - Dr?ger Medical - GE Healthcare - Masimo - MEDTRONIC - Mindray - Omron Healthcare - OSI Systems - PHILIPS HEALTHCARE - Roche - Schiller - Second Opinion Telemedicine . - Smiths Medical - St. Jude Medical - Welch Allyn For more information visit http://www.researchandmarkets.com/research/f3...ced_remote
CMD: 71.58 (+0.41), BSX: 13.50 (+0.12), ABT: 43.67 (-0.04), MDT: 71.85 (+2.66), STJ: 65.06 (-0.11), OSIS: 68.78 (+0.34)
Vipshop Leads 4 Top Stocks With Bolting RS Lines
at Investor's Business Daily - Tue Nov 18, 7:02AM CST
Going with the flow is all well and good, but rising head and shoulders above the crowd is a sign of a solid stock. Today's Screen of the Day features four companies that have bolting Relative Strength lines. An RS line tracks how a stock is doing...
ZTS: 44.01 (-0.22), ABT: 43.67 (-0.04), VIPS: 23.08 (-0.91), BIDU: 242.40 (-1.75), PFE: 30.66 (+0.34), JMEI: 22.79 (-0.85), COST: 138.93 (+0.46), IDXX: 150.09 (+0.68), LITB: 7.47 (-0.30), BABA: 111.85 (-2.40)
DexCom Still A Favorite Diabetes Stock
Bill Gunderson - at Seeking Alpha - Mon Nov 17, 10:15AM CST
DexCom (NASDAQ: DXCM ) continues to be one of my favorite diabetes stocks. DexCom, founded in 1999 and based right here in my hometown of San Diego, California, is a medical device company that makes continuous glucose monitoring (CGM) systems. ...
JNJ: 108.95 (+0.65), ABT: 43.67 (-0.04), DXCM: 51.71 (-0.03), MDT: 71.85 (+2.66)
People with Chronic Obstructive Pulmonary Disease (COPD) Who Received Nutrition Treatment in the Hospital Had Better Health Outcomes
PR Newswire - Mon Nov 17, 9:00AM CST
People aged 65 and older, who were being treated for chronic obstructive pulmonary disease (COPD) in the hospital and received nutrition treatment (oral nutrition supplements) had reduced lengths of stay, hospital costs and chances of returning to the hospital within 30-days, according to a study published in CHEST.1
ABT: 43.67 (-0.04)
Zoetis buys Abbott's animal health business
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 8:16AM CST
ZTS: 44.01 (-0.22), ABT: 43.67 (-0.04)
Watch for Abbott Laboratories to Potentially Rebound After Falling 1.75% Yesterday
Comtex SmarTrend(R) - Fri Nov 14, 4:10PM CST
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $43.68 to a high of $44.59. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $43.94 on volume of 4.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ABT: 43.67 (-0.04)
Abbott Laboratories (ABT) Showing Signs Of Being Water-Logged And Getting Wetter
at The Street - Fri Nov 14, 2:42PM CST
Trade-Ideas LLC identified Abbott Laboratories (ABT) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
ABT: 43.67 (-0.04)
Global Clinical Chemistry Analyzer (Basic Metabolic, Electrolyte, Liver, Lipid, Renal, Thyroid Function, Specialty Chemicals) Market - Forecast to 2019
M2 - Fri Nov 14, 5:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/jzzrg4/clinical) has announced the addition of the "Clinical Chemistry Analyzer Market by Product, Test Type, End User - Global Forecast to 2019" report to their offering. Clinical chemistry analyzers are the most widely used equipments in clinical laboratories. A large quantity of reagents and other consumables are required for various types of tests. Basic metabolic panel tests are the largest test segment for the clinical chemistry analyzer market in 2014, whereas the lipid profile test segment is expected to grow at the highest CAGR between 2014 and 2019. Growth in the basic metabolic panel tests, aided by growing trends of preventive medicine and increasing incidence in lifestyle disease will drive the growth of the market. This report segments the global clinical chemistry analyzer market into analyzers, reagents and other products. The market is further sub segmented into Small (400-800 Test/H), Medium (800-1,200 Tests/H), Large (1,200-2,000 Tests/H), Very large (2,000 Tests/H). The clinical chemistry reagents market is sub segmented into calibrators, controls, standards and other reagents. The major players in the clinical chemistry analyzer market include Roche Diagnostics (Switzerland), Beckman Coulter (U.S.) Abbott Diagnostics (U.S.) Siemens AG (Germany), Ortho-Clinical Diagnostics (U.S.), Thermo Fisher Scientific (U.S.) Randox Laboratories Ltd. (U.K.), ElitechGroup (France), Mindray (China), Horiba (Japan). Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Insights 7 Clinical Chemistry Analyzers Market, By Product 8 Clinical Chemistry Analyzers Market, By Test 9 Clinical Chemistry Analyzers Market, By End Users 10 Geographic Analysis 11 Competitive Landscape 12 Company Profiles 13 Appendix Companies Mentioned: - Abbott Laboratories - Danaher Corporation - Elitech - F. Hoffmann-La Roche - Horiba - Johnson & Johnson - Mindray Medical International Limited - Randox Laboratories - Siemens - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/jzzrg4/clinical
JNJ: 108.95 (+0.65), ABT: 43.67 (-0.04), DHR: 82.43 (+0.06), MR: 30.88 (-0.34)
Total Return And Dividend Growth Investing
David Crosetti - at Seeking Alpha - Thu Nov 13, 2:50PM CST
KO: 42.77 (-0.15), JNJ: 108.95 (+0.65), ABT: 43.67 (-0.04), LMT: 186.25 (+0.74), KMB: 113.49 (-0.16), TGT: 66.80 (-0.33), WMT: 83.69 (+0.12), MCD: 96.26 (+0.29), PG: 87.83 (-0.01), CL: 67.89 (-0.03)
11 Earnings Reports Worth Paying Attention To
Brian Nelson - at Seeking Alpha - Thu Nov 13, 1:03PM CST
KO: 42.77 (-0.15), YHOO: 52.06 (-0.31), T: 35.72 (-0.13), ABT: 43.67 (-0.04), NSC: 114.99 (-0.84), UTX: 108.68 (+1.31), BRCM: 42.41 (+0.23), DDD: 35.78 (+0.45), KMB: 113.49 (-0.16), BA: 130.19 (+1.77), CLB: 137.99 (-0.04)
Research and Markets: Global Cardiac Biomarkers Market 2014-2018 with Abbott Laboratories, Alere, Ortho Clinical Diagnostics & Roche Diagnostics Dominating
Business Wire - Thu Nov 13, 8:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/9c49lp/global_cardiac) has announced the addition of the "Global Cardiac Biomarkers Market 2014-2018" report to their offering.
ABT: 43.67 (-0.04)
Research and Markets: Global BGM Device Market 2014-2018 with Abbott Laboratories, Arkray, Bayer Healthcare, F. Hoffmann-La Roche & LifeScan Dominating
Business Wire - Thu Nov 13, 8:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/bph2ng/global_bgm_device) has announced the addition of the "Global BGM Device Market 2014-2018" report to their offering.
ABT: 43.67 (-0.04)
Defibrillator Market to 2018 - Abbott Laboratories, Alere Inc., Ortho Clinical Diagnostics Inc. and Roche Diagnostics Analyzed
PRWeb - Thu Nov 13, 6:50AM CST
The Global Defibrillator Market 2014-2018 report says one of the major trends upcoming in the Defibrillator market is the growing use of multifunction defibrillators. The most important driver of the cardiovascular devices market is increased incidence of cardiac disorders. It is used to deliver a therapeutic dose of electrical energy in the form of electric shocks to the heart muscle for restoring normal heart rhythms.
ABT: 43.68 (-0.03), ALR: 40.13 (+0.13)
Global Cardiac Biomarkers Market 2014-2018 with Abbott Laboratories, Alere, Ortho Clinical Diagnostics & Roche Diagnostics Dominating
M2 - Thu Nov 13, 5:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/kbxkrr/global_cardiac) has announced the addition of the "Global Cardiac Biomarkers Market 2014-2018" report to their offering. The analysts forecast the Global Cardiac Biomarkers market to grow at a CAGR of 12.75% over the period 2013-2018 A cardiac biomarker is defined as a measurable substance that is an indicator used in the diagnosis and risk stratification related to cardiovascular disease (CVDs) such as acute coronary syndrome (ACS), coronary syndromes, myocardial infarction (MI), and heart failure. Some of the cardiac biomarkers include creatine kinase (CK) MB, troponins (cTnI and cTnT), BNP, NT-proBNP, GFAP, H-FABP, LDH isoenzymes, D-dimer, IMA, MPO, myoglobin, and sCD40L. Cardiac biomarker assays help medical professionals to understand and differentiate between myocardial infarction and angina, which assists in the diagnosis and treatment of CVDs. The abnormal concentration of these biomarkers will act as significant predictors of an adverse cardiovascular condition. Cardiac point of care (POC) testing offers reliable measurement of cardiac biomarkers and provides results within one hour of testing. In addition to saving time, some cardiac POC tests have been modified to improve the accuracy of the measurement of enzymes to reduce operational error. The identification of new cardiac biomarkers (H-FABP, GPBB, Urotensin II, and S-100 as potential cardiac biomarkers) and the advances being made in diagnostic technologies are some of the major trends uocoming in this market. According to the report, one of the major factors driving this market is the increase in the incidence of cardiac disorders. This increase in the incidence of CVDs, HF, and coronary syndromes is leading to increased adoption of cardiac POC tests because they provide rapid diagnostics for analyzing the specificity of the disease. Further, the report states that one key challenge in the market is the lack of specific measures to detect the presence of CVDs, which may have an adverse effect on patients because it may lead to incorrect diagnosis, and in serious cardiac conditions it may even cause death Key Vendors - Abbott Laboratories - Alere - Ortho Clinical Diagnostics - Roche Diagnostics For more information visit http://www.researchandmarkets.com/research/kb...al_cardiac
ABT: 43.68 (-0.03)
Global BGM Device Market 2014-2018 with Abbott Laboratories, Arkray, Bayer Healthcare, F. Hoffmann-La Roche & LifeScan Dominating
M2 - Thu Nov 13, 5:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/5x4zcw/global_bgm_device) has announced the addition of the "Global BGM Device Market 2014-2018" report to their offering. Diabetes is a disease that occurs when the body is unable to produce insulin, or when the glucose rises above the required levels. Insulin, a hormone produced by the pancreas, is used to process glucose, which acts as a fuel for the tissues. BGM is the process of testing the concentration of insulin or glucose in the blood. A blood glucose meter is a small electronic device used to measure and display the blood glucose level. To measure the level of blood glucose, a small drop of blood is taken by pricking a finger with an instrument called a lancet. The blood is then placed on a disposable blood glucose test strip and this is inserted into a blood glucose meter. One key trend emerging in the market is the change in the preference of patients to take advantage of home healthcare rather than going to hospitals. The move toward proactive monitoring rather than waiting for treatment is opening up new opportunities for the Global BGM Device market. According to the report, one of the main drivers in this market is the increasing incidence of diabetic patients. The increase in the prevalence of diabetes and the high market potential of diabetes products has encouraged various companies to explore the Global BGM Device market. Further, the report states that one of the main challenges in the market is the high cost of BGM devices. Despite the numerous benefits, the high cost of BGM devices hinders their acceptability among patients. Many patients do not have the required funds to invest in a device. To calculate the market size, the report considers the revenue generated from the sales of the three segments as mentioned below: - Blood Glucose Strips - Blood Glucose Meters - Lancets Key Vendors - Abbott Laboratories - Arkray - Bayer Healthcare - F. Hoffmann-La Roche - LifeScan For more information visit http://www.researchandmarkets.com/research/5x...bgm_device
ABT: 43.68 (-0.03)
Global Insulin Delivery Devices Market Outlook 2018
M2 - Thu Nov 13, 4:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/ttg7ws/global_insulin) has announced the addition of the "Global Insulin Delivery Devices Market Outlook 2018" report to their offering. In 2013, a total of 382 Million People had diabetes and by 2030 this number is expected to rise to 552 Million. This finding by the International Diabetes Federation (IDF) and similar results from studies done by organizations of repute such as WHO, CDC, NHS, etc., suggest that a huge patient population exists in the diabetes market. In 2013, health expenditure on diabetes accounted for around 10% of the total health expenditure globally. Of all the market segments that result from this multibillion dollar expenditure, insulin delivery devices represents one of the most rapidly expanding areas and is thus the key focus of this current study. In this latest research study Global Insulin Delivery Devices Market Outlook 2018, the analysts identified the market dynamics in various important regions to highlight the areas offering promising opportunities to companies for boosting their growth. Insulin delivery devices predominantly include Insulin Syringes, Insulin Pens (Disposable and Reusable), Insulin Pumps and Insulin Jet Injectors. Our study provides a comprehensive analysis of the delivery devices market, both at global and regional levels. This analysis includes the current market statistics, key drivers stimulating each segment's growth, and the future outlook of the segments. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Global Insulin Market Overview to 2018 4. Industry Trends and Drivers 5. Key Market Restraints 6. Global Insulin Delivery Devices Market Outlook to 2018 7. Insulin Delivery Devices: Current and Future Outlook to 2018 8. Emerging Devices 9. Key Players Companies Mentioned: - Abbott Laboratories - B. Braun Melsungen AG - Becton Dickinson - Eli Lilly - F. Hoffmann La Roche - Insulet Corporation - Johnson and Johnson - Medtronic - Novo Nordisk - Sanofi-Aventis - Ypsomed Holding AG For more information visit http://www.researchandmarkets.com/research/tt...al_insulin
JNJ: 108.95 (+0.65), ABT: 43.68 (-0.03), PODD: 44.89 (+0.14), NVO: 44.18 (+0.58), MDT: 71.85 (+2.66), LLY: 67.95 (+0.66)
Abbott Laboratories' (ABT) Presents at Credit Suisse Healthcare Conference -- Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 4:19PM CST
ABT: 43.68 (-0.03)
DexCom Scales 52-Week High on Product Pipeline Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 1:10PM CST
Impressive third-quarter 2014 results, recent FDA approvals for its new products along with a robust product pipeline contribute to the growth trajectory of DexCom, Inc. (DXCM), creating good momentum for 2015 as well.
ABT: 43.68 (-0.03), JNJ: 108.95 (+0.65), DXCM: 51.71 (-0.03), MDT: 71.85 (+2.66)
ABT Recent Posts: http://investorshangout.com/Abbott-Laboratories-ABT-49973/
ABT Abbott Laboratories Recent Headline News
Cancer Diagnostics (Tumor Biomarker Tests, Imaging, Endoscopy and Biopsy) Market 2014 - 2020
M2 - 2 hrs 20 mins ago
Research and Markets (http://www.researchandmarkets.com/research/cgz62c/cancer) has announced the addition of the "Cancer Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. Imaging, endoscopy, biopsy and tumor biomarker tests altogether comprise the global cancer diagnostics market. Imaging for cancer detection remains the largest segment in the cancer diagnostics market owing to its utilization in detection of almost every cancer type. MRI, PET, CT, mammography and ultrasound are the major imaging modalities, of which, CT scan and ultrasound imaging account for more than two-third of the total cancer imaging market. A tumor biomarker test is a segment in the cancer diagnostics market with highest research activity. Cancer biomarkers are increasingly being applied in cancer diagnostics; a highly sensitive and specific biomarker essentially helps in better diagnosis, monitoring and prognosis of cancer. Protein-based biomarkers such as alpha-fetoprotein (AFP), cancer embryonic antigen (CEA), prostate-specific antigen (PSA) are among the prominently used tumor biomarkers. The market for cancer diagnostics is majorly driven by demand from the patients affected with cancers of lung, breast, and colorectal cancer. Lung cancer is the most common cancer of all types and approximately 1.8 billion new cases of lung cancer were diagnosed in 2012. The increasing use of tobacco products in developing nations, particularly in BRICS countries, is contributing to the growing prevalence of lung cancer in the world. In 2013, the global lung cancer diagnostics market accounted for one-fourth of the global cancer diagnostics market revenue. In addition, the rising prevalence of breast cancer among women across the world, particularly in the Asia Pacific, is expected to drive the market for breast cancer diagnostics at the highest CAGR of 8.2% during the forecast period 2014 to 2020. The global cancer diagnostics market is led by players such as Abbott Laboratories, Ambry Genetics, AstraZeneca, bioMerieux, Eli Lilly and Co., Roche, GlaxoSmithKline plc, Novartis, and Pfizer. Scope of the Report Tumor Biomarker Tests: - PSA Tests - CTC Tests - AFP Tests - CA 19-9 - CA 125 - EGFR - HER2 - CEA - BRCA - KRAS - ALK Imaging - MRI Scan - PET Scan - CT Scan - Mammography - Ultrasound Endoscopy - Bronchoscopy - Colonoscopy - Sigmoidoscopy - Colposcopy - Others Biopsy - Bone Marrow Biopsy - Needle Biopsy - Endoscopic Biopsy Cancer Diagnostics Market, by Application: - Leukemia - Breast Cancer - Colorectal Cancer - Kidney - Liver - Lung - Ovarian - Pancreatic - Prostate Companies Mentioned - Abbott Laboratories, Inc. - Ambry Genetics - AstraZeneca plc - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Genoptix, Inc. - GlaxoSmithKline plc - Pfizer, Inc. - bioMeriux SA For more information visit http://www.researchandmarkets.com/research/cgz62c/cancer
ABT: 43.67 (-0.04), PFE: 30.66 (+0.34), AZN: 73.72 (+1.22), LLY: 67.95 (+0.66), GSK: 46.12 (+0.24), NVS: 95.58 (+1.20)
qPCR and dPCR Markets (Instruments, Reagents, Software/Services, Clinical and Research Markets) Report 2013-2018
M2 - 2 hrs 25 mins ago
Research and Markets (http://www.researchandmarkets.com/research/tv8xlw/qpcr_and_dpcr) has announced the addition of the "qPCR and dPCR Markets (Instruments, Reagents, Software/Services, Clinical and Research Markets)" report to their offering. Real time qPCR is considered the gold standard for accurate, sensitive, and fast quantification of nucleic acid sequences. PCR technologies, specifically qPCR (quantitative PCR) and digital PCR (dPCR) show significant promise for growth. qPCR is mainly a workhorse in the research laboratory, while dPCR is helping to push the potential for diagnostic applications due to its sensitivity, precision, robustness and reproducibility. qPCR has been established for a broad range of applications including gene expression, genotyping, pathogen detection, DNA methylation analysis. qPCR is increasingly being used in the medical diagnostic arena for diagnosis of bacterial disease, detection of antibiotic resistance, diagnosis of infectious disease and quantification of bacterial load. It is also used to detect genetic abnormalities and cancer mutations. qPCR-based diagnostic tests are expected to expand in the coming years. dPCR provides absolute measurement of copies and would seem to be the next logical step in PCR evolution. dPCR partitions the sample and reaction components into hundreds or thousands of reaction chambers to count the presence or absence of molecules. It provides greatly improved sensitivity in the detection of rare mutations and sequences. This technology will become increasingly important in the clinical application of PCR. Segments Include: - Clinical Market for qPCR - Research Market for qPCR - Clinical Market for dPCR - Research Market for dPCR - qPCR Instruments - qPCR Reagents - qPCR Software and Services - dPCR Instruments - dPCR Reagents - dPCR Software and Services Some of the market drivers influencing participation: - A global aging population - An increase in the number of population affected by chronic medical conditions - Advancements in gene detection and technologies - The increasing role of diagnostics in home health and remote patient care - Personalized medicine - Advancements next generation sequencing and multi-gene approaches Challenges facing those in the market, including: - Development financial, time investment risk - Uncertain regulatory environment - Cost to patient may limit accessibility in many regions - Economic uncertainty: patients are likely to decline advanced testing in times of hardship - New technologies more difficult to develop Some of the issues and trends affecting this market are: - BRIC Involvement - qPCR and Robotics - Lab-on-a-Chip Devices - Molecular Testing Reimbursement Companies profiles in this report include: - Abbott Laboratories - Affymetrix - Aglient Technologies - Analytik Jena AG - Becton Dickinson - BioFire Diagnostics - bioMerieux - Bio-Rad Laboratories - Cephid - Denville Scientific - Eppendorf AG - Exiqon A/S - Fluidigm - Illumina - Kyratec - Life Techologies - Promega - Qiagen - RainDance Technologies - Roche - Sacace Biotechnologies - Takaro Bio - Thermo Fisher Scientific - WaferGen Biosystems For more information visit http://www.researchandmarkets.com/research/tv...r_and_dpcr
ABT: 43.67 (-0.04)
Advanced Remote Patient Monitoring Systems Market Report: 2014 Edition
M2 - 2 hrs 31 mins ago
Research and Markets (http://www.researchandmarkets.com/research/f348f9/advanced_remote) has announced the addition of the "Advanced Remote Patient Monitoring Systems, 7th Edition" report to their offering. For their potential to reduce healthcare costs and improve patient outcomes, patient monitoring systems with advanced capabilities are among the fastest-growing devices in terms of revenue growth. In recent years, there's been demand from healthcare organizations for monitors with remote reporting functions and EMR transfer. Advanced Remote Patient Monitoring Systems, is a comprehensive study on the patient monitoring industry, including the advanced system with remote and wireless capability to includes patient monitoring equipment and devices which have advanced features. The report specifically focuses on technologically advanced (including wireless and remote) patient monitors; monitors with patient data processing applications; and monitors which are capable of data transfer to an EMR system-including equipment and peripherals which coordinate the flow of data to hospital electronic medical record systems. For the most part, devices covered in this report can: 1) provide monitoring information beyond a patient room; and 2) provide data for an EMR system or are expected to add such features within the forecast period. This report provides complete market sizes and revenue breakouts for the important segments of the advanced monitoring market. For the purpose of this report, three general areas of advanced patient monitoring are covered. - Blood Management and Function Monitors - Glucose Monitor, Blood Pressure Monitor, PT/INR, Other - Cardiac Event and Function Monitors - Cardiac Event, EKG/ECG - Neurological Event Monitors - Respiratory Function Monitors - Anesthesia - General - Sleep Apnea There are a considerable number of companies offering some form of wireless and remote technologies, patient data processing applications and equipment, and EMR data transfer equipment. A select few are profiled in this report including: - Abbott Laboratories - Aerotel Medical Systems - Alere - AMD Global Telemedicine - American TeleCare - AuthentiDate - B. Braun - Baxter - Bosch - Boston Scientific - C.R. Bard - Cardiocom - Carematix - Compumedics . - Covidien - Criticare Systems - Dr?ger Medical - GE Healthcare - Masimo - MEDTRONIC - Mindray - Omron Healthcare - OSI Systems - PHILIPS HEALTHCARE - Roche - Schiller - Second Opinion Telemedicine . - Smiths Medical - St. Jude Medical - Welch Allyn For more information visit http://www.researchandmarkets.com/research/f3...ced_remote
CMD: 71.58 (+0.41), BSX: 13.50 (+0.12), ABT: 43.67 (-0.04), MDT: 71.85 (+2.66), STJ: 65.06 (-0.11), OSIS: 68.78 (+0.34)
Vipshop Leads 4 Top Stocks With Bolting RS Lines
at Investor's Business Daily - Tue Nov 18, 7:02AM CST
Going with the flow is all well and good, but rising head and shoulders above the crowd is a sign of a solid stock. Today's Screen of the Day features four companies that have bolting Relative Strength lines. An RS line tracks how a stock is doing...
ZTS: 44.01 (-0.22), ABT: 43.67 (-0.04), VIPS: 23.08 (-0.91), BIDU: 242.40 (-1.75), PFE: 30.66 (+0.34), JMEI: 22.79 (-0.85), COST: 138.93 (+0.46), IDXX: 150.09 (+0.68), LITB: 7.47 (-0.30), BABA: 111.85 (-2.40)
DexCom Still A Favorite Diabetes Stock
Bill Gunderson - at Seeking Alpha - Mon Nov 17, 10:15AM CST
DexCom (NASDAQ: DXCM ) continues to be one of my favorite diabetes stocks. DexCom, founded in 1999 and based right here in my hometown of San Diego, California, is a medical device company that makes continuous glucose monitoring (CGM) systems. ...
JNJ: 108.95 (+0.65), ABT: 43.67 (-0.04), DXCM: 51.71 (-0.03), MDT: 71.85 (+2.66)
People with Chronic Obstructive Pulmonary Disease (COPD) Who Received Nutrition Treatment in the Hospital Had Better Health Outcomes
PR Newswire - Mon Nov 17, 9:00AM CST
People aged 65 and older, who were being treated for chronic obstructive pulmonary disease (COPD) in the hospital and received nutrition treatment (oral nutrition supplements) had reduced lengths of stay, hospital costs and chances of returning to the hospital within 30-days, according to a study published in CHEST.1
ABT: 43.67 (-0.04)
Zoetis buys Abbott's animal health business
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 8:16AM CST
ZTS: 44.01 (-0.22), ABT: 43.67 (-0.04)
Watch for Abbott Laboratories to Potentially Rebound After Falling 1.75% Yesterday
Comtex SmarTrend(R) - Fri Nov 14, 4:10PM CST
Abbott Laboratories (NYSE:ABT) traded in a range yesterday that spanned from a low of $43.68 to a high of $44.59. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $43.94 on volume of 4.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ABT: 43.67 (-0.04)
Abbott Laboratories (ABT) Showing Signs Of Being Water-Logged And Getting Wetter
at The Street - Fri Nov 14, 2:42PM CST
Trade-Ideas LLC identified Abbott Laboratories (ABT) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
ABT: 43.67 (-0.04)
Global Clinical Chemistry Analyzer (Basic Metabolic, Electrolyte, Liver, Lipid, Renal, Thyroid Function, Specialty Chemicals) Market - Forecast to 2019
M2 - Fri Nov 14, 5:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/jzzrg4/clinical) has announced the addition of the "Clinical Chemistry Analyzer Market by Product, Test Type, End User - Global Forecast to 2019" report to their offering. Clinical chemistry analyzers are the most widely used equipments in clinical laboratories. A large quantity of reagents and other consumables are required for various types of tests. Basic metabolic panel tests are the largest test segment for the clinical chemistry analyzer market in 2014, whereas the lipid profile test segment is expected to grow at the highest CAGR between 2014 and 2019. Growth in the basic metabolic panel tests, aided by growing trends of preventive medicine and increasing incidence in lifestyle disease will drive the growth of the market. This report segments the global clinical chemistry analyzer market into analyzers, reagents and other products. The market is further sub segmented into Small (400-800 Test/H), Medium (800-1,200 Tests/H), Large (1,200-2,000 Tests/H), Very large (2,000 Tests/H). The clinical chemistry reagents market is sub segmented into calibrators, controls, standards and other reagents. The major players in the clinical chemistry analyzer market include Roche Diagnostics (Switzerland), Beckman Coulter (U.S.) Abbott Diagnostics (U.S.) Siemens AG (Germany), Ortho-Clinical Diagnostics (U.S.), Thermo Fisher Scientific (U.S.) Randox Laboratories Ltd. (U.K.), ElitechGroup (France), Mindray (China), Horiba (Japan). Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Insights 7 Clinical Chemistry Analyzers Market, By Product 8 Clinical Chemistry Analyzers Market, By Test 9 Clinical Chemistry Analyzers Market, By End Users 10 Geographic Analysis 11 Competitive Landscape 12 Company Profiles 13 Appendix Companies Mentioned: - Abbott Laboratories - Danaher Corporation - Elitech - F. Hoffmann-La Roche - Horiba - Johnson & Johnson - Mindray Medical International Limited - Randox Laboratories - Siemens - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/jzzrg4/clinical
JNJ: 108.95 (+0.65), ABT: 43.67 (-0.04), DHR: 82.43 (+0.06), MR: 30.88 (-0.34)
Total Return And Dividend Growth Investing
David Crosetti - at Seeking Alpha - Thu Nov 13, 2:50PM CST
KO: 42.77 (-0.15), JNJ: 108.95 (+0.65), ABT: 43.67 (-0.04), LMT: 186.25 (+0.74), KMB: 113.49 (-0.16), TGT: 66.80 (-0.33), WMT: 83.69 (+0.12), MCD: 96.26 (+0.29), PG: 87.83 (-0.01), CL: 67.89 (-0.03)
11 Earnings Reports Worth Paying Attention To
Brian Nelson - at Seeking Alpha - Thu Nov 13, 1:03PM CST
KO: 42.77 (-0.15), YHOO: 52.06 (-0.31), T: 35.72 (-0.13), ABT: 43.67 (-0.04), NSC: 114.99 (-0.84), UTX: 108.68 (+1.31), BRCM: 42.41 (+0.23), DDD: 35.78 (+0.45), KMB: 113.49 (-0.16), BA: 130.19 (+1.77), CLB: 137.99 (-0.04)
Research and Markets: Global Cardiac Biomarkers Market 2014-2018 with Abbott Laboratories, Alere, Ortho Clinical Diagnostics & Roche Diagnostics Dominating
Business Wire - Thu Nov 13, 8:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/9c49lp/global_cardiac) has announced the addition of the "Global Cardiac Biomarkers Market 2014-2018" report to their offering.
ABT: 43.67 (-0.04)
Research and Markets: Global BGM Device Market 2014-2018 with Abbott Laboratories, Arkray, Bayer Healthcare, F. Hoffmann-La Roche & LifeScan Dominating
Business Wire - Thu Nov 13, 8:12AM CST
Research and Markets (http://www.researchandmarkets.com/research/bph2ng/global_bgm_device) has announced the addition of the "Global BGM Device Market 2014-2018" report to their offering.
ABT: 43.67 (-0.04)
Defibrillator Market to 2018 - Abbott Laboratories, Alere Inc., Ortho Clinical Diagnostics Inc. and Roche Diagnostics Analyzed
PRWeb - Thu Nov 13, 6:50AM CST
The Global Defibrillator Market 2014-2018 report says one of the major trends upcoming in the Defibrillator market is the growing use of multifunction defibrillators. The most important driver of the cardiovascular devices market is increased incidence of cardiac disorders. It is used to deliver a therapeutic dose of electrical energy in the form of electric shocks to the heart muscle for restoring normal heart rhythms.
ABT: 43.68 (-0.03), ALR: 40.13 (+0.13)
Global Cardiac Biomarkers Market 2014-2018 with Abbott Laboratories, Alere, Ortho Clinical Diagnostics & Roche Diagnostics Dominating
M2 - Thu Nov 13, 5:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/kbxkrr/global_cardiac) has announced the addition of the "Global Cardiac Biomarkers Market 2014-2018" report to their offering. The analysts forecast the Global Cardiac Biomarkers market to grow at a CAGR of 12.75% over the period 2013-2018 A cardiac biomarker is defined as a measurable substance that is an indicator used in the diagnosis and risk stratification related to cardiovascular disease (CVDs) such as acute coronary syndrome (ACS), coronary syndromes, myocardial infarction (MI), and heart failure. Some of the cardiac biomarkers include creatine kinase (CK) MB, troponins (cTnI and cTnT), BNP, NT-proBNP, GFAP, H-FABP, LDH isoenzymes, D-dimer, IMA, MPO, myoglobin, and sCD40L. Cardiac biomarker assays help medical professionals to understand and differentiate between myocardial infarction and angina, which assists in the diagnosis and treatment of CVDs. The abnormal concentration of these biomarkers will act as significant predictors of an adverse cardiovascular condition. Cardiac point of care (POC) testing offers reliable measurement of cardiac biomarkers and provides results within one hour of testing. In addition to saving time, some cardiac POC tests have been modified to improve the accuracy of the measurement of enzymes to reduce operational error. The identification of new cardiac biomarkers (H-FABP, GPBB, Urotensin II, and S-100 as potential cardiac biomarkers) and the advances being made in diagnostic technologies are some of the major trends uocoming in this market. According to the report, one of the major factors driving this market is the increase in the incidence of cardiac disorders. This increase in the incidence of CVDs, HF, and coronary syndromes is leading to increased adoption of cardiac POC tests because they provide rapid diagnostics for analyzing the specificity of the disease. Further, the report states that one key challenge in the market is the lack of specific measures to detect the presence of CVDs, which may have an adverse effect on patients because it may lead to incorrect diagnosis, and in serious cardiac conditions it may even cause death Key Vendors - Abbott Laboratories - Alere - Ortho Clinical Diagnostics - Roche Diagnostics For more information visit http://www.researchandmarkets.com/research/kb...al_cardiac
ABT: 43.68 (-0.03)
Global BGM Device Market 2014-2018 with Abbott Laboratories, Arkray, Bayer Healthcare, F. Hoffmann-La Roche & LifeScan Dominating
M2 - Thu Nov 13, 5:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/5x4zcw/global_bgm_device) has announced the addition of the "Global BGM Device Market 2014-2018" report to their offering. Diabetes is a disease that occurs when the body is unable to produce insulin, or when the glucose rises above the required levels. Insulin, a hormone produced by the pancreas, is used to process glucose, which acts as a fuel for the tissues. BGM is the process of testing the concentration of insulin or glucose in the blood. A blood glucose meter is a small electronic device used to measure and display the blood glucose level. To measure the level of blood glucose, a small drop of blood is taken by pricking a finger with an instrument called a lancet. The blood is then placed on a disposable blood glucose test strip and this is inserted into a blood glucose meter. One key trend emerging in the market is the change in the preference of patients to take advantage of home healthcare rather than going to hospitals. The move toward proactive monitoring rather than waiting for treatment is opening up new opportunities for the Global BGM Device market. According to the report, one of the main drivers in this market is the increasing incidence of diabetic patients. The increase in the prevalence of diabetes and the high market potential of diabetes products has encouraged various companies to explore the Global BGM Device market. Further, the report states that one of the main challenges in the market is the high cost of BGM devices. Despite the numerous benefits, the high cost of BGM devices hinders their acceptability among patients. Many patients do not have the required funds to invest in a device. To calculate the market size, the report considers the revenue generated from the sales of the three segments as mentioned below: - Blood Glucose Strips - Blood Glucose Meters - Lancets Key Vendors - Abbott Laboratories - Arkray - Bayer Healthcare - F. Hoffmann-La Roche - LifeScan For more information visit http://www.researchandmarkets.com/research/5x...bgm_device
ABT: 43.68 (-0.03)
Global Insulin Delivery Devices Market Outlook 2018
M2 - Thu Nov 13, 4:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/ttg7ws/global_insulin) has announced the addition of the "Global Insulin Delivery Devices Market Outlook 2018" report to their offering. In 2013, a total of 382 Million People had diabetes and by 2030 this number is expected to rise to 552 Million. This finding by the International Diabetes Federation (IDF) and similar results from studies done by organizations of repute such as WHO, CDC, NHS, etc., suggest that a huge patient population exists in the diabetes market. In 2013, health expenditure on diabetes accounted for around 10% of the total health expenditure globally. Of all the market segments that result from this multibillion dollar expenditure, insulin delivery devices represents one of the most rapidly expanding areas and is thus the key focus of this current study. In this latest research study Global Insulin Delivery Devices Market Outlook 2018, the analysts identified the market dynamics in various important regions to highlight the areas offering promising opportunities to companies for boosting their growth. Insulin delivery devices predominantly include Insulin Syringes, Insulin Pens (Disposable and Reusable), Insulin Pumps and Insulin Jet Injectors. Our study provides a comprehensive analysis of the delivery devices market, both at global and regional levels. This analysis includes the current market statistics, key drivers stimulating each segment's growth, and the future outlook of the segments. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Global Insulin Market Overview to 2018 4. Industry Trends and Drivers 5. Key Market Restraints 6. Global Insulin Delivery Devices Market Outlook to 2018 7. Insulin Delivery Devices: Current and Future Outlook to 2018 8. Emerging Devices 9. Key Players Companies Mentioned: - Abbott Laboratories - B. Braun Melsungen AG - Becton Dickinson - Eli Lilly - F. Hoffmann La Roche - Insulet Corporation - Johnson and Johnson - Medtronic - Novo Nordisk - Sanofi-Aventis - Ypsomed Holding AG For more information visit http://www.researchandmarkets.com/research/tt...al_insulin
JNJ: 108.95 (+0.65), ABT: 43.68 (-0.03), PODD: 44.89 (+0.14), NVO: 44.18 (+0.58), MDT: 71.85 (+2.66), LLY: 67.95 (+0.66)
Abbott Laboratories' (ABT) Presents at Credit Suisse Healthcare Conference -- Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 4:19PM CST
ABT: 43.68 (-0.03)
DexCom Scales 52-Week High on Product Pipeline Strength - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 1:10PM CST
Impressive third-quarter 2014 results, recent FDA approvals for its new products along with a robust product pipeline contribute to the growth trajectory of DexCom, Inc. (DXCM), creating good momentum for 2015 as well.
ABT: 43.68 (-0.03), JNJ: 108.95 (+0.65), DXCM: 51.71 (-0.03), MDT: 71.85 (+2.66)
(0)
(0)Abbott Laboratories (ABT) Stock Research Links
Scroll down for more posts ▼